Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.22.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 6,420 $ 6,037
Restricted cash 165 295
Receivables 101 112
Inventory 469 293
Prepaid expenses and other current assets 544 480
Discontinued operations - current assets 14 12
Total current assets 7,713 7,229
Property and equipment, net 317 420
Other assets 48 48
Operating lease right-of-use asset 241 297
Total assets 8,319 7,994
Current liabilities:    
Accounts payable 443 795
Accrued clinical trials expenses 36 9
Other accrued liabilities 631 314
Operating lease liability, current 117 112
Deferred grant revenue 165 295
Discontinued operations - current liabilities 1,132 1,144
Total current liabilities 2,524 2,669
Operating lease liability, non-current 128 187
Total liabilities 2,652 2,856
Stockholders' equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000shares authorized, 14,629,217 and 9,914,158 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively. 15 10
Additional paid-in capital 386,709 381,183
Accumulated deficit (381,057) (376,055)
Total stockholders' equity 5,667 5,138
Total liabilities and stockholders' equity $ 8,319 $ 7,994